

Clayton Howard Hudnall, M.D.
Urology San Antonio
7909 Fredericksburg Road
San Antonio, Texas 78229

EDUCATION:

1979-1980 University of Texas
 Austin, Texas
 Bachelors of Arts Degree in Business Administration

1980-1984 Southwestern Medical School
 Dallas, Texas
 Doctorate of Medicine Degree

1984-1985 University of Texas Health Science Center
 San Antonio, Texas
 Internship

1985-1990 University of Texas Health Science Center
 San Antonio, Texas
 Residency

WORK EXPERIENCE:

1996-Present Urology San Antonio Research, PA
 San Antonio, Texas
 Investigator

1990-Present Urology San Antonio, P.A.
 7909 Fredericksburg Road Suite 125
 San Antonio, Texas 78229
 Group Practice-Urologist

CREDENTIALS:

1992 Diplomate American Board of Urology

ACADEMIC APPOINTMENTS:

1990-Present University of Texas Health Science Center Division of Urology
 San Antonio, Texas
 Clinical Assistant Professor

HOSPITAL AFFILIATIONS:

1990-Present Baptist Healthcare Systems
 San Antonio, Texas

Medical Staff Member

1990-Present Christus Santa Rosa Healthcare Systems
San Antonio, Texas
Medical Staff Member

1990-Present Methodist Healthcare Systems
San Antonio, Texas
Medical Staff Member

PROFESSIONAL AFFILIATIONS:

Bexar County Medical Association

Texas Medical Association

CONSULTANT:

2004-Present GlaxoSmithKline

PUBLICATIONS:

1. Hudnall, C.H., Kirk, J.F., and Radwin, H.M. The Role of Posterior Lumbotomy in the Management of Surgical Stone Disease. "Journal of Urology," Vol. 139:704, 1988.
2. Hudnall, C.H., Erickson, D.R., and Sarosdy, M.F. Evaluation of Intracorporeal Prostaglandin E – 1 in the Treatment of Impotence – A Pilot Study. "Journal of Urology
3. Hudnall, C.H., Banowsky, L.H., Holzmann, J., and Centeno, A. The Use of Pediatric Allografts in Adult Recipients. "Journal of Urology."

CLINICAL RESEARCH EXPERIENCE:

1. "Open – Label Study of the Efficacy and Safety Of An Aqueous XXXXX Topical Cream In The Treatment of Erectile Dysfunction."
2. "Phase III, Efficacy And Safety Of An Aqueous XXXXX Topical Cream In The Treatment Of Erectile Dysfunction."
3. "A Multi – Center, Randomized, Placebo Controlled, Two Period (Clinic, Home) Efficacy and Safety Study Of Intraurethral Administered XXXXX In The Treatment Of Mild To Moderate Erectile Dysfunction."
4. "A Phase II, Safety Study Of 5mg XXXXX Versus Placebo In The Treatment Of Patients Diagnosed With Male Erectile Dysfunction Following A Bilateral Nerve – Sparing Radical Retropubic Prostatectomy."
5. "A Phase III, Efficacy And Safety Study Of Three Fixed Doses Of XXXXX SL Tablets 2, 4, And 5 mg Versus Placebo In The Treatment Of Male Erectile Dysfunction."

6. "A Randomized, Double – Blind, Multicenter, Phase III Study Of XXXXX And XXXXX In The Treatment Of Chronic Bacterial Prostatitis."
7. "A Multicenter Study Of XXXXX In Patients With Prostate Cancer IN Whom GnRH Agonists Are Contraindicated."
8. "A Phase III, Multicenter, Open – Label, Randomized Study Of XXXXX vs. XXXXX, In Patients With Prostate Cancer Who Are Candidates For Initial."
9. "A Phase III, Multicenter, Open – Label Study of XXXXX to Achieve Prostate Gland Volume Reduction In Patients With Prostate Cancer Prior To Definitive Local Therapy."
10. "A Phase II/III, Double – Blind, Placebo Controlled, Dose – Finding Study of the Safety And Efficacy Of XXXXX In Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)."
11. "An Eleven – Week, Open – Label, Randomized, Multicenter, Parallel – Design, Placebo Lead – In – Study Of XXXXX Capsules, 0.4mg Daily Versus XXXXX Capsules, 5mg (with XXXXX) Daily in Patients With The Signs and Symptoms Of Benign Prostatic Hyperplasia."
12. "A Randomized, Double – Blind, Placebo Controlled, Parallel Group Study Of The Efficacy and Safety Of XXXXX In The Treatment And Modification Of Progression Of Benign Prostatic Hyperplasia."
13. "A Randomized, Double – Blind, Placebo Controlled, Two – Year, Parallel Group Study Of The Efficacy And Safety Of XXXXX 0.5mg In The Treatment And Prevention Of Progression Of Benign Prostatic Hyperplasia."
14. "A Phase II/III, Double – Blind, Placebo Controlled, Dose – Finding Study Of The Safety And Efficacy Of XXXXX In Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)."
15. "A Randomized, Double-blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXXXX Administered Once Daily for Four years to Reduce the risk of Biopsy-Detectable Prostate Cancer."
16. "The efficacy, onset of effect, and safety of XXXXX once daily in the treatment of lower urinary tract symptoms of Benign Prostatic Hyperplasia: A randomized, Placebo-Controlled trial using an acute international Prostate Score."
17. "A Randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of XXXXX administered once daily for four years to reduce the risk of biopsy-detectable prostate cancer."
18. "A multi-center, double-blind, placebo-controlled, dose-titration study of XXXXX transdermal systems in patients with overactive bladder."
19. "A multi-center, randomized, parallel group, double-blind, placebo controlled, flexible dose escalation study to evaluate sexual and relationship satisfaction in the female partner of men with Erectile dysfunction treated with XXXXX in the United States."
20. "A pilot study to evaluate increasing the area of application and rotating site of application of XXXXX on application site reactions."
21. "A double-blind, placebo-controlled, randomized US study to evaluate the effect of XXXXX prolonged release on nocturia in patients with symptoms of overactive bladder (OAB)."

22. "A phase 2, randomized, double-blind, placebo-controlled study of the safety and efficacy of XXXXX topical solution in patients with Interstitial Cystitis."
23. "Efficacy and safety of XXXXX compared with placebo in women with symptoms of mixed urinary incontinence."
24. "A clinical trial evaluating the safety and efficacy of XXXXX in patients with hormone resistant prostate cancer with evaluated PSA without metastasis."
25. "The Effect of XXXXX compared to placebo on Bone Mineral Density in patients undergoing Androgen Deprivation Therapy."
26. "Diagnostic Molecular Marker/s for Prostate Cancer."
27. "A placebo-controlled study evaluating the safety and efficacy of XXXXX 3mg and 5mg in Women with Overactive Bladder."
28. "A Phase III, open-label, multi-center, safety and efficacy study of XXXXX patients with Advanced Prostate Cancer."
29. "A randomized, double-blind, placebo-controlled, multi-center efficacy and safety study of XXXXX for the prevention of bone fractures in Men with Prostate Cancer on Androgen Deprivation Therapy."
30. "An evaluation of Semen Characteristics after 40wks daily dosing with 20mg."
31. "An open-label, randomized, multi-center, parallel group comparison of the efficacy and safety of XXXXX at two different dosing regimens in patients with prostate cancer dosed for thirteen 28-day cycle."
32. "A randomized, double-blind, parallel, placebo-controlled study to evaluate the efficacy and safety of XXXX administered once daily to men with Erectile Dysfunction."
33. "A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with XXXXX (0.5) and XXXXX (0.4), administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia."
34. "A randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of XXXXX for the prevention of Prostate Cancer in Men with High Grade Prostatic Intraepithelial Neoplasia (PIN)."
35. "Diagnostic Molecular Marker for Prostate Cancer Screening."
36. "A multicenter, randomized, double-blind, study to evaluate the safety and efficacy of XXXXX Vaginal Ring releasing 4 mg /day versus 6 mg versus placebo in women diagnosed with Overactive Bladder who have symptoms of Predominant or pure urge incontinence, Urgency and Frequency."
37. "An open-label, multicentre, randomized parallel group comparison of efficacy and safety of XXXXthree-month depot in three different dosing regimens of 240 mg (40mg/ml) and 240 (60 mg/ml) in patients with Prostate Cancer requiring Androgen Ablation Therapy."
38. "A randomized, double-blind, placebo-controlled study to evaluate AMG 162 in the Treatment of Bone Loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer."

39. "An open-label study of the efficacy and safety of 5 and 10 mg XXXXX (XXXXX) in Patients with overactive bladder symptoms."
40. "A multicenter, double-blind, randomized study to compare the efficacy and safety of XXXX 750 MG once daily for five days versus XXXXX twice daily for ten days in the treatment of complicated urinary tract infection or acute Pyelonephritis."
41. "A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of XXXX in patients 18-70 years of age with symptoms of overactive Bladder."
42. "A phase 2, 8-week, multicenter, randomized double-blind, placebo controlled, parallel group study evaluating the efficacy, tolerability and safety of [X,X] XXXXX (XXXXX) for stress urinary incontinence in women."
43. "Psychometric Validation of the OAB family Impact Measure."
44. "Prospective, open-label, non-comparative, multi-center study to evaluate the efficacy and safety of XXXX extended-release (XXXX) 1000 mg tablets given once daily for 7 to 14 Days in the treatment of patients 18 years or older with complicated urinary tract infections Caused by pseudomonas aeruginosa and other common uropathogens."
45. "A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy of XXXX 15 mg OD on the increase in the warning time, the time sensation of urgency to voiding, in patients with overactive bladder (OAB)."
46. "A multicenter, Parallel-Arm, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of XXXX Administered Once Daily to Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia."
47. "A Phase 2 Randomized, Double-Blind, Dose-Ranging Efficacy and Safety Study of XXXX (10 mg, 25 mg, 50 mg), XXXX XXX (50 mg) Each vs Placebo in Subjects With Erectile Dysfunction."
48. "Multicenter Randomized Double-Blind, Placebo-Controlled Switch Study Of Men With Mild ED To Evaluate The Efficacy Of XXXX 8 Hours Post-Dose."
49. "A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdraw Effects of Chronic Daily and As Needed Dosing With XXXX in the Treatment of Premature Ejaculation."
50. "Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Group Dose Response Study To Assess the Efficacy and Safety of Oral XXXX in Men With Premature Ejaculation."
51. "A Phase 2 Multi-Center, Open Label, Long-term Extension Trail to Assess The Safety And Sustained Efficacy of Oral XXXX Administered As Required in Adult Men With Premature Ejaculation."
52. "A Randomized, Double-Blind, placebo-controlled, parallel arm, multi center trial Assessing the effect of daily treatment of XXXX 20 mg or XXXX 100 mg compared To placebo on spermatogenesis, mean sperm concentration, sperm count, morphology, Motility and reproductive hormones in healthy males or males with mild erectile dysfunction."
53. "Spouse: Surgical Prosthesis outcome and Satisfaction Evaluation"

54. "A randomized, double blind, placebo controlled, four arm (placebo, XXXX,XXXX, and XXXX XX plus XXXX) study to evaluate the clinical efficacy and safety of the XXXXX 4mg in men who have frequency and urgency, with or without urinary urge incontinence With or without bladder outlet obstruction."
55. "A Randomized, Double-Blind, Triple-Dummy, Parallel Group Study to Investigate the Effects of a Single Oral Dose of XXXX on Urodynamic Parameters With Overactive Bladder."
56. "A Placebo-Controlled, Randomized, Double-Blind, Fixed Dose, At-Home Study to Evaluate the Efficacy and Safety to Intranasally Administered XXXX in Subjects with Erectile Dysfunction."
57. "A Placebo-Controlled, Randomized, Double-Blind, Fixed-Dose, At-Home Study to Evaluate the Efficacy and Safety of Intranasally Administered XXXX in Subjects with Erectile Dysfunction and Diabetes Mellitus."
58. "A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy with XXXX in Subjects with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia."
59. "A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Evaluation of the Efficacy and Safety of XXXX in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia."
60. "A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 2 Dose Ranging Trial to Assess the Safety and Efficacy of XXXX Tablets in Male Subjects with Erectile Dysfunction."
61. "A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of XXXX for the Treatment of Symptomatic Benign Prostatic Hyperplasia."
62. "Phase II Study of XXXX XXXX in Patients with Bladder Cancer."
63. "A Multi-Centre Open-Label Evaluation of the Safety of XXXX in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia."
64. "A Phase II, Randomized, Multi-Centre, Placebo-Controlled, Double-Blind, Dose-Ranging Clinical Trial to Study the Efficacy and Safety of XXXX (XXXX) for the Treatment of Hot Flashes Following Surgical or Medical Castration of Prostate Cancer Patients."
65. "A Multi-Centre, Double-Blind Placebo-Controlled, Flexible-Dose Study with an Open-Label Phase to Assess the Efficacy of XXXX on Erectile Function and Intercourse as well as to Validate the Sexual Experience Questionnaire and its Treatment Responsiveness in Men with Erectile Dysfunction."
66. "An Open-Label, Multi-Center, Randomized, Parallel-Group Study, Investigating the Efficacy and Safety of XXXX One Month Dosing Regimens; XXXX) and XXXX), in Comparison to XXXX in Patients with Prostate Cancer Requiring Androgen Ablation Therapy."
67. "A Multi-Center, Randomized Clinical Investigation of XXXX Versus Continued Therapy in Patients Receiving XXXX or XXXX for Advanced Prostate Cancer."
68. "A Forty-Eight Week, Randomized Discontinuation Trial of XXXX in Women with Hypoactive Sexual Desire Disorder Containing an Open-Label, Flexible Dose Period Followed by a Double-Blind, Randomized, Placebo-Controlled Period."
69. "A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of XXXX in Women with Mixed Desire/Interest/Arousal/Orgasm Disorders."

70. "A Multi-Centre, Double-Blind, Randomized, Placebo-and Active-Controlled, Parallel-Group, Dose-Ranging Study of XXXX in Patients with Overactive Bladder."
71. "An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-term Safety and Tolerability of Different Three-Month XXXX Dosing Regimens, XXXX, XXXX, in Patients with Prostate Cancer."
72. "A Feasibility Evaluation of the XXXXX XXXXX in Facilitating the Vesico-urethral Anastomosis Following a Radical Prostatectomy."
73. "A Phase III Multi-Center, Open-Label, Randomized Evaluation in Hypogonadal Male Subjects of the Pharmacokinetics and Safety of a Dose Regimen of XXXXX, a Novel Testosterone Transmucosal Film Formulation, and Striant (Testosterone Buccal System) Mucoadhesive."
74. "A Phase III, open-label, multi-center study of the efficacy and safety of XXXXX in the treatment of patients with non-muscle invasive (superficial) bladder cancer at high risk of progression and who are refractory to BCG."
75. "A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Spermatogenesis in Healthy Male Subjects During Administration of XXXXX."
76. "A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Repeat Treatment with Two Dose Levels of XXXXX (XXXXX) XXXXX Followed by a Treatment with XXXXX in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity."
77. "A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trail of XXXXX 50 milligrams Daily and, with Uptitration, 100 Milligrams Daily in Premenopausal Women with Hypoactive Sexual Desire Disorder."
78. "A Phase III Radomized, Open-Label Study of XXXXX and XXXXX Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate cancer who are Chemotherapy-Naïve."
79. "Post-Marketing Study Using XXXXX for the Treatment of Benign Prostatic Hyperplasia (BPH)."
80. "A Multi-Center Clinical Study of the XXXXX for the Treatment of Localized (T1cT2a) Prostate Cancer with HIFU."
81. "A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of XXXXX in Extending the Time to Progression of Low-Risk Localized Prostate Cancer in Men who are Candidates for or Undergoing Expectant Management."
82. "A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-term Safety Study of XXXXX Testosterone Undecanoate in Hypogonadal Men."
83. "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of XXXXX Once-a-Day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia."
84. "XXXXX 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life."

85. "A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of XXXXX in Patients with Overactive Bladder."
86. "A Phase II Randomised, Two-way Crossover Study to Compare the Steady State Pharmacokinetics of Testosterone following application of different XXXXX doses in hypogonadal male subjects."
87. "A Phase III, Randomized, Double-Blind, Placebo-Controlled, and Open-Label Active-Controlled Study Evaluate the Safety and Efficacy of XXXXX Treatment in Men with Secondary Hypogonadism."
88. "A Phase 1 Trial of XXXXX Therapy for locally Recurrent Prostate Cancer without Metastases after Primary Radiation Therapy."
89. "A Multicentre, Placebo Controlled, Randomised, Double-Blind, Dose Ranging Study of XXXXX and Placebo Daily Doses for 4 Weeks in Patients Suffering From Overactive Bladder Syndrome."
90. "A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (XXXXX) in combination with XXXXX Administred Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk After Radical Prostatectomy."
91. "Pilot Study of the Intervesimal Administration of XXXXX Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer."
92. "Phase Ib placebo-controlled trial of XXXXX in the study of modulation of intermediate endpoint markers in patients with prostate cancer who are undergoing prostatectomy."
93. "A Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing with XXXXX to Treat the Symptoms of Overactive Bladder with a 14-Week Open-Label Safety Extension."
94. "A randomized double blind phase III study to evaluate adjuvant XXXXX treatment versus placebo in patients with clear cell XXXXX and high risk of recurrence."
95. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
96. "XXXXX IM dosage regimens in patients with symptomatic BPH, a 1 year placebo-controlled efficacy study and long-term safety assessment."
97. "A Randomized, Double-Blind, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of XXXXX in Men with Prostate Cancer Receiving Androgen Deprivation Therapy."
98. "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXXXX for the Treatment of Hypogonadal Men."
99. "Prospective Multi-Center Study to Evaluate the Diagnostic Performance of the XXXXX for Prostate Cancer Screening."
100. "An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of XXXXX One-Month Dosing Regimen in Patients with Prostate Cancer Requiring XXXXX."

101. "A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with XXXXX and XXXXX, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia"
102. "Long Term Effectiveness Trial for AMS Sling Systems MiniArc"
103. "A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXX vs. XXXXX in Combination XXXXX in Patients with Metastatic Hormone-Resistant Prostate Cancer and Bone Metastasis who are Pain-Free or Mildly Symptomatic"
104. "A Phase 3 Randomized, Open-Label Study of XXXXX in Combination with XXXXX and XXXXX Versus XXXXX and XXXXX in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain"
105. "TITAN OTR Clinical Trial"
106. "Evaluation of the PCA3 Assay and Algorithms Combining PCA3 Score with Other Factors for the Prediction of Biopsy Outcome and Pathological Stage"
107. "A Phase I, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability and Activity of XXXXX Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection"
108. "A Randomized, Double-Blind, Placebo Controlled, Parallel- Design, Multicenter Study to Evaluate the Urodynamic Effects of XXXXX Once-A-Day for 12 Weeks In Men with Signs and Symptoms of Benign Prostatic Hyperplasia"
109. "An Open-Label, Phase 3 Study of XXXXX Testosterone Gel 2% in Hypogonadal Males"
110. "A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a XXXXX in Comparison with XXXXX in Patients with Overactive Bladder"
111. "Prospective Randomized Double-Blind Study of Sperm Production in Healthy Volunteers Receiving XXXXX or Placebo"
112. "An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients with Locally Recurrent Prostate Cancer After Primary Radiation Therapy"
113. "A Multicenter, Open Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy in Combination with XXXXX Administered Every 3 Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy"
114. "A Phase 3, Multi-Center, Open-Label Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two 6-Month XXXXX Formulations in Subjects with Prostatic Adenocarcinoma"
115. "Performance Evaluation of Optimized Kit Components and Process"
116. "GeneSearch Prostate Methylation Urine (Pro Mu) Assay"
117. "A Randomized, Double-Blind, Placebo Controlled Multicenter Cross over study to Investigate the Pharmacodynamic Profile of XXXXX in Subjects with Pelvic Pain of Bladder Origin"